APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adipose Tissue-derived Stem Cell Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Adipose Tissue-derived Stem Cell Therapy Market Outlook and Growth Opportunities 2026

19 December 2025200 pages

Choose your research edition.

Industry ResearchAdipose Tissue-derived Stem Cell Therapy Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Adipose Tissue-derived Stem Cell Therapy Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Adipose Tissue-derived Stem Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adipose Tissue-derived Stem Cell Therapy Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Adipose Tissue-derived Stem Cell Therapy Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Adipose Tissue-derived Stem Cell Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Adipose Tissue-derived Stem Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Adipose Tissue-derived Stem Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adipose Tissue-derived Stem Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Adipose Tissue-derived Stem Cell Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Adipose Tissue-derived Stem Cell Therapy market include Lonza, Tissue Genesis, Pluristem Therapeutics, Pluristem Therapeutics, Mesoblast, iXCells Biotechnologies, Intrexon, Cytori Therapeutics and Cyagen, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Adipose Tissue-derived Stem Cell Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Adipose Tissue-derived Stem Cell Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Adipose Tissue-derived Stem Cell Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Adipose Tissue-derived Stem Cell Therapy market.

Adipose Tissue-derived Stem Cell Therapy Segment by Company

Lonza

Tissue Genesis

Pluristem Therapeutics

Pluristem Therapeutics

Mesoblast

iXCells Biotechnologies

Intrexon

Cytori Therapeutics

Cyagen

Corestem

Celltex Therapeutics Corporation

Cellleris

Celgene Corporation

BioRestorative Therapies

Antria

AlloCure

Adipose Tissue-derived Stem Cell Therapy Segment by Type

Autologous Stem Cells

Allogeneic Stem Cells

Adipose Tissue-derived Stem Cell Therapy Segment by Application

Therapeutic Application

Research Application

Adipose Tissue-derived Stem Cell Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Adipose Tissue-derived Stem Cell Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Adipose Tissue-derived Stem Cell Therapy key companies, revenue, market share, and recent developments.

3. To split the Adipose Tissue-derived Stem Cell Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Adipose Tissue-derived Stem Cell Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Adipose Tissue-derived Stem Cell Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Adipose Tissue-derived Stem Cell Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adipose Tissue-derived Stem Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adipose Tissue-derived Stem Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adipose Tissue-derived Stem Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Adipose Tissue-derived Stem Cell Therapy industry.

Chapter 3: Detailed analysis of Adipose Tissue-derived Stem Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Adipose Tissue-derived Stem Cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Adipose Tissue-derived Stem Cell Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Adipose Tissue-derived Stem Cell Therapy Industry Trends Table 2. Adipose Tissue-derived Stem Cell Therapy Industry Drivers Table 3. Adipose Tissue-derived Stem Cell Therapy Industry Opportunities and Challenges Table 4. Adipose Tissue-derived Stem Cell Therapy Industry Restraints Table 5. Global Adipose Tissue-derived Stem Cell Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Adipose Tissue-derived Stem Cell Therapy Revenue Share by Company (2021-2026) Table 7. Global Adipose Tissue-derived Stem Cell Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Adipose Tissue-derived Stem Cell Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Adipose Tissue-derived Stem Cell Therapy Company, Product Type & Application Table 10. Global Adipose Tissue-derived Stem Cell Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Adipose Tissue-derived Stem Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Autologous Stem Cells Table 15. Significant Companies of Allogeneic Stem Cells Table 16. Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type (2021-2026) Table 20. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Therapeutic Application Table 22. Significant Companies of Research Application Table 23. Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application (2021-2026) Table 27. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application (2027-2032) Table 28. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Region (2021-2026) Table 31. Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Region (2027-2032) Table 33. Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Market Share by Country (2021-2026) Table 36. Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Market Share by Country (2027-2032) Table 38. Lonza Company Information Table 39. Lonza Business Overview Table 40. Lonza Adipose Tissue-derived Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Lonza Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 42. Lonza Recent Development Table 43. Tissue Genesis Company Information Table 44. Tissue Genesis Business Overview Table 45. Tissue Genesis Adipose Tissue-derived Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Tissue Genesis Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 47. Tissue Genesis Recent Development Table 48. Pluristem Therapeutics Company Information Table 49. Pluristem Therapeutics Business Overview Table 50. Pluristem Therapeutics Adipose Tissue-derived Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Pluristem Therapeutics Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 52. Pluristem Therapeutics Recent Development Table 53. Pluristem Therapeutics Company Information Table 54. Pluristem Therapeutics Business Overview Table 55. Pluristem Therapeutics Adipose Tissue-derived Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Pluristem Therapeutics Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 57. Pluristem Therapeutics Recent Development Table 58. Mesoblast Company Information Table 59. Mesoblast Business Overview Table 60. Mesoblast Adipose Tissue-derived Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Mesoblast Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 62. Mesoblast Recent Development Table 63. iXCells Biotechnologies Company Information Table 64. iXCells Biotechnologies Business Overview Table 65. iXCells Biotechnologies Adipose Tissue-derived Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. iXCells Biotechnologies Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 67. iXCells Biotechnologies Recent Development Table 68. Intrexon Company Information Table 69. Intrexon Business Overview Table 70. Intrexon Adipose Tissue-derived Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Intrexon Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 72. Intrexon Recent Development Table 73. Cytori Therapeutics Company Information Table 74. Cytori Therapeutics Business Overview Table 75. Cytori Therapeutics Adipose Tissue-derived Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Cytori Therapeutics Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 77. Cytori Therapeutics Recent Development Table 78. Cyagen Company Information Table 79. Cyagen Business Overview Table 80. Cyagen Adipose Tissue-derived Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Cyagen Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 82. Cyagen Recent Development Table 83. Corestem Company Information Table 84. Corestem Business Overview Table 85. Corestem Adipose Tissue-derived Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Corestem Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 87. Corestem Recent Development Table 88. Celltex Therapeutics Corporation Company Information Table 89. Celltex Therapeutics Corporation Business Overview Table 90. Celltex Therapeutics Corporation Adipose Tissue-derived Stem Cell Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Celltex Therapeutics Corporation Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 92. Celltex Therapeutics Corporation Recent Development Table 93. Cellleris Company Information Table 94. Cellleris Business Overview Table 95. Cellleris Adipose Tissue-derived Stem Cell Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Cellleris Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 97. Cellleris Recent Development Table 98. Celgene Corporation Company Information Table 99. Celgene Corporation Business Overview Table 100. Celgene Corporation Adipose Tissue-derived Stem Cell Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Celgene Corporation Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 102. Celgene Corporation Recent Development Table 103. BioRestorative Therapies Company Information Table 104. BioRestorative Therapies Business Overview Table 105. BioRestorative Therapies Adipose Tissue-derived Stem Cell Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. BioRestorative Therapies Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 107. BioRestorative Therapies Recent Development Table 108. Antria Company Information Table 109. Antria Business Overview Table 110. Antria Adipose Tissue-derived Stem Cell Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Antria Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 112. Antria Recent Development Table 113. AlloCure Company Information Table 114. AlloCure Business Overview Table 115. AlloCure Adipose Tissue-derived Stem Cell Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. AlloCure Adipose Tissue-derived Stem Cell Therapy Product Portfolio Table 117. AlloCure Recent Development Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Adipose Tissue-derived Stem Cell Therapy Product Image Figure 2. Global Adipose Tissue-derived Stem Cell Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adipose Tissue-derived Stem Cell Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Adipose Tissue-derived Stem Cell Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Autologous Stem Cells Image Figure 8. Allogeneic Stem Cells Image Figure 9. Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type (2021-2032) Figure 12. Therapeutic Application Image Figure 13. Research Application Image Figure 14. Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application (2021-2032) Figure 17. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Adipose Tissue-derived Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 20. North America Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Adipose Tissue-derived Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Adipose Tissue-derived Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Adipose Tissue-derived Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 26. South America Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Adipose Tissue-derived Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Autologous Stem Cells
  • Allogeneic Stem Cells
Applications
  • Therapeutic Application
  • Research Application
Companies covered
  • Lonza
  • Tissue Genesis
  • Pluristem Therapeutics
  • Pluristem Therapeutics
  • Mesoblast
  • iXCells Biotechnologies
  • Intrexon
  • Cytori Therapeutics
  • Cyagen
  • Corestem
  • Celltex Therapeutics Corporation
  • Cellleris
  • Celgene Corporation
  • BioRestorative Therapies
  • Antria
  • AlloCure

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Adipose Tissue-derived Stem Cell Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Adipose Tissue-derived Stem Cell Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Adipose Tissue-derived Stem Cell Therapy Market Dynamics
  1. 2.1 Adipose Tissue-derived Stem Cell Therapy Industry Trends
  2. 2.2 Adipose Tissue-derived Stem Cell Therapy Industry Drivers
  3. 2.3 Adipose Tissue-derived Stem Cell Therapy Industry Opportunities and Challenges
  4. 2.4 Adipose Tissue-derived Stem Cell Therapy Industry Restraints
3 Adipose Tissue-derived Stem Cell Therapy Market by Company
  1. 3.1 Global Adipose Tissue-derived Stem Cell Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Adipose Tissue-derived Stem Cell Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Adipose Tissue-derived Stem Cell Therapy Company Ranking (2024-2026)
  4. 3.4 Global Adipose Tissue-derived Stem Cell Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Adipose Tissue-derived Stem Cell Therapy Company Product Type and Application
  6. 3.6 Global Adipose Tissue-derived Stem Cell Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Adipose Tissue-derived Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Adipose Tissue-derived Stem Cell Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Adipose Tissue-derived Stem Cell Therapy Market by Type
  1. 4.1 Adipose Tissue-derived Stem Cell Therapy Type Introduction
  2. 4.1.1 Autologous Stem Cells
  3. 4.1.2 Allogeneic Stem Cells
  4. 4.2 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Type
  5. 4.2.1 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type (2021-2032)
5 Adipose Tissue-derived Stem Cell Therapy Market by Application
  1. 5.1 Adipose Tissue-derived Stem Cell Therapy Application Introduction
  2. 5.1.1 Therapeutic Application
  3. 5.1.2 Research Application
  4. 5.2 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Application
  5. 5.2.1 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Application (2021-2032)
  7. 5.2.3 Global Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application (2021-2032)
6 Adipose Tissue-derived Stem Cell Therapy Regional Value Analysis
  1. 6.1 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Adipose Tissue-derived Stem Cell Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Adipose Tissue-derived Stem Cell Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Adipose Tissue-derived Stem Cell Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Adipose Tissue-derived Stem Cell Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Adipose Tissue-derived Stem Cell Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
7 Adipose Tissue-derived Stem Cell Therapy Country-level Value Analysis
  1. 7.1 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Adipose Tissue-derived Stem Cell Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Adipose Tissue-derived Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Adipose Tissue-derived Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lonza
  2. 8.1.1 Lonza Company Information
  3. 8.1.2 Lonza Business Overview
  4. 8.1.3 Lonza Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Lonza Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  6. 8.1.5 Lonza Recent Developments
  7. 8.2 Tissue Genesis
  8. 8.2.1 Tissue Genesis Company Information
  9. 8.2.2 Tissue Genesis Business Overview
  10. 8.2.3 Tissue Genesis Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Tissue Genesis Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  12. 8.2.5 Tissue Genesis Recent Developments
  13. 8.3 Pluristem Therapeutics
  14. 8.3.1 Pluristem Therapeutics Company Information
  15. 8.3.2 Pluristem Therapeutics Business Overview
  16. 8.3.3 Pluristem Therapeutics Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pluristem Therapeutics Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  18. 8.3.5 Pluristem Therapeutics Recent Developments
  19. 8.4 Pluristem Therapeutics
  20. 8.4.1 Pluristem Therapeutics Company Information
  21. 8.4.2 Pluristem Therapeutics Business Overview
  22. 8.4.3 Pluristem Therapeutics Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pluristem Therapeutics Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  24. 8.4.5 Pluristem Therapeutics Recent Developments
  25. 8.5 Mesoblast
  26. 8.5.1 Mesoblast Company Information
  27. 8.5.2 Mesoblast Business Overview
  28. 8.5.3 Mesoblast Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mesoblast Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  30. 8.5.5 Mesoblast Recent Developments
  31. 8.6 iXCells Biotechnologies
  32. 8.6.1 iXCells Biotechnologies Company Information
  33. 8.6.2 iXCells Biotechnologies Business Overview
  34. 8.6.3 iXCells Biotechnologies Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 iXCells Biotechnologies Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  36. 8.6.5 iXCells Biotechnologies Recent Developments
  37. 8.7 Intrexon
  38. 8.7.1 Intrexon Company Information
  39. 8.7.2 Intrexon Business Overview
  40. 8.7.3 Intrexon Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Intrexon Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  42. 8.7.5 Intrexon Recent Developments
  43. 8.8 Cytori Therapeutics
  44. 8.8.1 Cytori Therapeutics Company Information
  45. 8.8.2 Cytori Therapeutics Business Overview
  46. 8.8.3 Cytori Therapeutics Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Cytori Therapeutics Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  48. 8.8.5 Cytori Therapeutics Recent Developments
  49. 8.9 Cyagen
  50. 8.9.1 Cyagen Company Information
  51. 8.9.2 Cyagen Business Overview
  52. 8.9.3 Cyagen Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cyagen Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  54. 8.9.5 Cyagen Recent Developments
  55. 8.10 Corestem
  56. 8.10.1 Corestem Company Information
  57. 8.10.2 Corestem Business Overview
  58. 8.10.3 Corestem Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Corestem Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  60. 8.10.5 Corestem Recent Developments
  61. 8.11 Celltex Therapeutics Corporation
  62. 8.11.1 Celltex Therapeutics Corporation Company Information
  63. 8.11.2 Celltex Therapeutics Corporation Business Overview
  64. 8.11.3 Celltex Therapeutics Corporation Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Celltex Therapeutics Corporation Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  66. 8.11.5 Celltex Therapeutics Corporation Recent Developments
  67. 8.12 Cellleris
  68. 8.12.1 Cellleris Company Information
  69. 8.12.2 Cellleris Business Overview
  70. 8.12.3 Cellleris Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Cellleris Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  72. 8.12.5 Cellleris Recent Developments
  73. 8.13 Celgene Corporation
  74. 8.13.1 Celgene Corporation Company Information
  75. 8.13.2 Celgene Corporation Business Overview
  76. 8.13.3 Celgene Corporation Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Celgene Corporation Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  78. 8.13.5 Celgene Corporation Recent Developments
  79. 8.14 BioRestorative Therapies
  80. 8.14.1 BioRestorative Therapies Company Information
  81. 8.14.2 BioRestorative Therapies Business Overview
  82. 8.14.3 BioRestorative Therapies Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  83. 8.14.4 BioRestorative Therapies Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  84. 8.14.5 BioRestorative Therapies Recent Developments
  85. 8.15 Antria
  86. 8.15.1 Antria Company Information
  87. 8.15.2 Antria Business Overview
  88. 8.15.3 Antria Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Antria Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  90. 8.15.5 Antria Recent Developments
  91. 8.16 AlloCure
  92. 8.16.1 AlloCure Company Information
  93. 8.16.2 AlloCure Business Overview
  94. 8.16.3 AlloCure Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  95. 8.16.4 AlloCure Adipose Tissue-derived Stem Cell Therapy Product Portfolio
  96. 8.16.5 AlloCure Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst